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Historically, HIV vaccines specifically designed to raise cellular immunity resulted in protection from disease progression but not infection
when tested in monkeys challenged with a single high virus exposure. An alternative approach, more analogous to human sexual exposures, is to
repetitively challenge immunized monkeys with a much lower dose of virus until systemic infection is documented. Using these conditions to
mimic human sexual transmission, we found that a multi-protein DNA/MVA HIV-1 vaccine is indeed capable of protecting rhesus monkeys
against systemic infection when repeatedly challenged with a highly heterologous immunodeficiency virus (SHIV). Furthermore, this repetitive
challenge approach allowed us to calculate per-exposure probability of infection, an observed vaccine efficacy of 64%, and undertake a systematic
analysis for correlates of protection based on exposures needed to achieve infection. Therefore, improved non-human primate models for vaccine
efficacy can provide novel insight and perhaps renew expectations for positive outcomes of human HIV clinical trials.
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doi:10.1016/j.virol.2006.04.0051 isolates representing different subtypes and dissimilar
circulating recombinant forms. Given that greater than 5 million
people were newly infected with HIV-1 in 2004 (AIDS epidemic
update, 2004; Joint United Nations Programme on HIV/AIDS
[http://www.unaids.org]), it is imperative that such a vaccine is
developed and made available for worldwide distribution.
Currently, there are approximately 35 preventive HIV
vaccines in human trials worldwide (IAVI Report, 2005; IAVI
[http://www.iavireport.org]). Among these, several approaches
have been developed that raise cellular immunity and protect
rhesus monkeys from AIDS caused by high dose challenges
with SHIV-89.6P, although they do not prevent infection by the
challenge virus. These approaches include: vaccination with
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with a recombinant MVA encoding matched SHIV Gag, Pol and
Env proteins (Amara et al., 2001); vaccinations with plasmid
DNA encoding SHIV Gag and Env proteins and plasmid
encoding IL-2/Ig (Barouch and Letvin, 2000); vaccination with
defective adenovirus vectors encoding SHIV Gag protein
(Shiver et al., 2002); and vaccinations with attenuated vesicular
stomatitis virus vectors encoding Env and Gag proteins (Rose
et al., 2001).
In the past, HIV vaccine regimens, including vaccines
designed to specifically induce cellular immunity (Allen et al.,
2000; Barouch et al., 2001a; Vogel et al., 2002), have been
tested in non-human primates by administering a single high
dose of SIV or SHIV either by intravenous injection (Barouch
and Letvin, 2000; Rose et al., 2001; Seaman et al., 2005; Shiver
et al., 2002) or intrarectal or intravaginal challenges (Amara et
al., 2001; Lena et al., 2002). This historical approach uses doses
of virus that are much higher than those observed during natural
transmissions of HIV where multiple exposures generally occur
for infection (Chakraborty et al., 2001; Gray et al., 2001; Tachet
et al., 1999). Furthermore, the per-exposure risk of infection is
100% in monkeys with this high dose of virus, whereas the per-
exposure risk of HIV infection in humans is generally estimated
to be in the range of 0.01–10%. The highest level of vRNA
detected in semen of men with acute HIV-1 subtype B infections
(without sexually transmitted diseases) is 105.24 copies/mL
(mean ± SD for that study, 4.1 ± 1.14 log10 copies/mL (Pilcher
et al., 2004). The minimal transmission rate for the average
heterosexual male with acute HIV-1 infection has been
predicted to be 0.0047 (1 transmission event/213 episodes
of intercourse), suggesting that the male would transmit virus
to 2%–6% of female sex partners within the first 2 months of
the acute infection (Pilcher et al., 2004).
An alternative, albeit more demanding, approach than the
single standard high virus dose is to repetitively challenge with a
lower dose of virus similar to that observed in human semen.
Several groups have demonstrated that repetitivemucosal SIVand
SHIV challenges result in successful transmission and systemic
infection of macaques, and these investigators are using different
routes of exposure, including vaginal, rectal and oral (Ma et al.,
2004; McDermott et al., 2004; Otten et al., 2005; Van Rompay et
al., 2005). For comparison to the single higher dose, Otten et al.
have shown that 10 TCID of SHIV162P3 was successfully
transmitted 33% of the time (3 infections after a total of 9 intra-
vaginal exposures) in female pig-tailed macaques (Otten et al.,
2005). Moreover, this challenge dose was approximately 5-fold
higher than HIV-1 RNA levels in human semen during acute
infection, a period of accepted high transmission risk (Cohen and
Pilcher, 2005). Lastly, Otten et al. have shown that the repetitive-
exposure, non-human primate model can be used successfully to
conduct preclinical studies focused on interventions to prevent
transmission (Otten et al., 2005).
The purpose of our present study was to determine whether
an HIV-1 DNA/MVA vaccine could provide protection from
infection using repetitive intrarectal exposures with doses of a
heterologous challenge virus (SHIV) that more closely parallel
viral loads observed in semen. We report that vaccinatedmacaques were significantly less likely to be infected than naïve
control animals and 25% of the vaccinated monkeys (4/16)
showed protection from infection after 18 or more virus
exposures. These findings provide the first direct evidence that a
multi-protein DNA/MVA vaccine can successfully prevent
highly heterologous transmissions in a model that more closely
mimics human sexual transmission.
Results
Repetitive intrarectal challenges
Vaccinated monkeys were challenged 7–11 months after
completing an immunogenicity trial of an HIV-1 CRF02_AG
DNA prime-MVA boost regimen (Ellenberger et al., 2005) to
investigate whether the monkeys would be protected from
heterologous SHIV challenges using repetitive intrarectal
exposures. Two naïve monkeys were included; one monkey
became systemically infected after 2 challenges and the second
monkey after 8 exposures. Historical rhesus macaque naïve
controls (n = 12) when challenged under identical conditions,
including the same virus stock of SHIV162P3 were shown to be
infected after an average of 4.6 exposures (range 1–14 exposures)
with only a single animal remaining uninfected after 14 exposures
(data not shown). Monkeys were considered systemically
infected by documented evidence of plasma viremia and
confirmed by provirus detection in PBMC.Among the vaccinated
monkeys, nine were infected with 6 or fewer exposures and one
was infected after 10 exposures. However, quite remarkably, 6 of
these 16 (37.5%) vaccinated monkeys remained protected from
systemic-infection after 17 challenges; well beyond what is
necessary to achieve infection of the naive control monkeys (Fig.
1). Furthermore, 4 of these 6 monkeys that remained protected
from systemic infection were not infected by 18 or more
exposures and in fact, one animal (99H) was selected to receive
8 additional challenges for a total of 26 without evidence of
systemic infection. With the inclusion of the 12 additional rhesus
naïve controls, as a group, the 16 vaccinated animals were 2.6-
fold less likely to be infected than 14 naïve control monkeys (Cox
hazard model, P = 0.027; hazard ratio is 0.391).
Assessment of vaccine efficacy
Based on a per-exposure transmission probability model,
the outcome of the challenge study indicated a significant
“leaky vaccine” effect (P = 0.007). Under this partial
protection model, the maximum likelihood estimate of vaccine
efficacy was 0.64, indicating a 64% reduction in the
probability of infection per exposure among vaccinated
animals compared to the 14 naïve control animals. The
corresponding 95% confidence interval for vaccine efficacy
was (0.26, 0.83). Comparison of the log likelihood values for
the leaky model and an all-or-none model suggests that the
leaky model demonstrates superior fit. Further evidence that
the partial protection model fit the animal challenge data well
is provided by the excellent agreement between the observed
survival curve and an expected survival curve from the fitted
Fig. 1. SHIV challenge survival curves. Comparison of expected (dashed line) and observed (solid line) survival curves of weekly SHIV challenges. The expected
curve was calculated based on the fitted leaky vaccine model to the SHIV challenge study data.
218 D. Ellenberger et al. / Virology 352 (2006) 216–225leaky vaccine model (Fig. 1). The expected curve is based on
the maximum likelihood estimates of vaccine efficacy (0.64)
and the per-exposure transmission probability (0.203) from the
fitted leaky vaccine model to the SHIV challenge study data.
A goodness-of-fit assessment also indicated adequate fit of the
leaky model (P = 0.35).
Viremia as a secondary endpoint
Most successful HIV vaccine regimens have controlled
viremia following infection by either SIV or SHIV high-dose
exposure. Therefore, the plasma viral load profiles of theFig. 2. Viral load profiles. Plasma levels of viral RNA are reported as copies per m
immunized animals and gray lines indicate naïve controls. The time of challenge thvaccinated animals that became systemically infected (n = 12)
were compared to that of 14 naïve control monkeys (Fig. 2).
There was a significant difference in the viral load peak when
the vaccinated animal group (geometric mean, 2.1 × 105; range
1.1 × 104–1.8 × 106 RNA copies/mL plasma) was compared to
the naïve control group (geometric mean, 5.5 × 106; range
2.2 × 105–2.9 × 108 RNA copies/mL plasma), P value = 0.0002.
However, the viral load for the vaccinated group over time
(area under the curve) was not significantly lower than the
naïve control group (geometric mean, 5.5 × 103; range
7.5 × 102–8.2 × 104 versus geometric mean, 1.9 × 104; range
2.7 × 102–4.1 × 107 RNA copies/mL), P value = 0.244.illiliter. The sensitivity limit is 100 copies/mL of plasma. Dark lines indicate
at resulted in infection is week 0.
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Based on the number of exposures needed to achieve
infection (Table 1), 10 animals were considered most
susceptible to infection while 6 animals, remaining uninfected
after 17 or more exposures (∼4-fold beyond the average
exposures for non-vaccinated animals), were considered least
susceptible. These groupings of relative susceptibility were then
used to investigate correlates of protection by comparing
vaccine-induced pre-challenge immunogenicity data. At the
peak cellular response, 1 week post-MVA, the mean Gag and
Env CRF02_AG temporal ELISPOT responses for each group
(most susceptible vs. least susceptible) were essentially
identical (Figs. 3A and B). At memory time point, 8 weeks
after the MVA boost, the mean Gag ELISPOT responses among
the least-susceptible group of animals was approximately 2-fold
greater then the most-susceptible animals (Fig. 3C). The Env
ELISPOT responses at the memory time point were too low to
reasonably evaluate (data not shown). To test for an association
between these ELISPOT responses and risk of infection, a Cox
proportional hazards model was fit using data from vaccinees
only with the cellular response as the sole covariate (Figs. 3D, E
and F). However, none of the associations achieved statistical
significance, but there was a trend for memory Gag ELISPOT
responses and risk of infection (P = 0.06).
In addition, other immune response parameters were
examined to investigate correlates of protection. In the memory
phase, the mean cross-subtype cellular responses to Gag
peptides from diverse HIV-1 subtypes A, AE, and B (Fig. 4)
between the groups were essentially identical. These data wereTable 1
Mucosal challenges and HLA typing










M547 2 Infected A*02 W201
14J 2 Infected A*08 W201
AC83 2 Infected
AC65 5 Infected A*02 W201
AC82 5 Infected A*08
M509 5 Infected A*02, A*08 W201
60J 5 Infected
04K 6 Infected W201
12I 6 Infected W201
AC36 10 Infected A*08, B*01
Least
susceptible f
06K 18 Infected A*08 W201
M562 18 No infection W201
86H 18 No infection W201
02L 19 Infected W201
94J 19 No infection A*08
99H 26 No infection
a Number of mucosal challenges received.
b Cell-free and cell-associated virus load assays were positive.
c Rhesus MHC Class I: A*01, A*02, A*08, A*11, B*01, B*03, B*04 and
B*17.
d Rhesus MHC Class II: DR*W201 and *0401/06.
e Ten vaccinated animals that were infected by 10 or less mucosal challenges.
f Six vaccinated animals that resisted systemic infection for 17 or more
mucosal challenges.also tested for an association between the immune response and
risk of infection with the Cox proportional hazards model (as
described above) but statistical significance was not achieved
(data not shown). In addition, pre-challenge humoral immunity
was investigated by measuring neutralizing antibody, binding
antibody, and anti-Env antibody to a CRF02_AG virus
(Ellenberger et al., 2005), but no differences were revealed
between the two groups of immunized animals based on
susceptibility to infection (data not shown).
Major histocompatibility complex-typing of animals
Since genetic haplotypes of the major histocompatibility
complex can influence mammalian immune responses and
susceptibility to infection, genetic typing of the 16 vaccinated
monkeys was completed (Table 1). As expected in an outbred
population, the genetic haplotypes among this animal cohort
were unique. Importantly, neither Mamu-A*01 nor Mamu-
B*17 animals were among those studied, as both these Mamu
alleles have been previously associated with control of
SIVmac239 infection (O'Connor et al., 2003). We compared
the genetic haplotypes of the most susceptible animals to the
least susceptible group and no significant associations with
susceptibility were found except that all 3 Mamu-A*02-positive
animals fell within the most susceptible group and were infected
by 6 or less virus challenges.
Tests for subclinical infection
Inguinal lymph node biopsies were performed on 2 monkeys
that had no evidence of systemic infection after 18 exposures.
By using a quantitative DNA-PCR assay sensitive to 1 proviral
copy per 105 cells, lymph node extracts from these monkeys
showed no evidence of SHIV provirus; thereby supporting their
virus-free status (data not shown). Inguinal lymph biopsies were
also taken from two vaccinated animals that had become
systemically infected after 6 exposures and as expected,
provirus was detected at a significant level in both macaques
(data not shown).
The possibility remained that the 4 immunized animals
without evidence of systemic infection (after 18 exposures)
harbored a low-level viral infection. Therefore, 3 months after
the animals received their last viral challenge 3 of these animals
were administered antibody cM-T807 to ablate the CD8+ T-cell
population while the other received a control antibody (IVIg).
The cM-T807 antibody treatment resulted in the near total
depletion of CD8+ T cells within 72 h (Fig. 5A). However, no
systemic viremia emerged in these treated animals over the
course of the 28-day follow-up (Fig. 5B). Two systemically
infected vaccinated animals that had controlled plasma viremia
to below detection were also administered cM-T807 (Fig. 5C).
In these animals, plasma viremia increased by three to four
orders of magnitude immediately upon CD8+ cell ablation and
decreased rapidly following the reemergence of the CD8+ Tcell
population (Fig. 5D).
Upon euthanasia, gut-associated lymphoid tissue, spleen,
lymph nodes, and testes were harvested from all macaques.
Fig. 3. Vaccination-induced pre-challenge ELISPOT responses. (A and B) Temporal ELISPOT Gag and Env responses at 1 week after the MVA boost. All animals
were tested against 5 Gag and 7 Env peptide pools. (C) ELISPOT Gag response at 8 weeks after the MVA boost. Symbols designate the total response of each
individual animal. The bold bar represents the arithmetic mean of each designated group. The animals have the same symbols in panels A, B and C. D, E, and F. Test
for an association between the ELISPOT response and risk of infection. The immunized but systemically infected monkeys are represented by open squares and
monkeys without evidence of systemic infection are represented by filled squares.
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co-cultured. There was evidence of spreading viral infection in
26% (23/87) of the infected macaque (n = 12) tissue lymphocyte
co-cultures including approximately 50% (15/31) of the lymphFig. 4. Temporal IFN-γ ELISPOT Gag responses to cross-subtype peptide pools
at 8 weeks after the MVA boost. The symbols designate the height of the total
ELISPOT response for individual animals and the bold bar indicates the
arithmetic mean height for the response in each group. Designations below the
panel specify the HIV-1 subtype. The animals have the same symbols as in Figs.
3A, B, and C.node-derived tissue co-cultures, but none (0/34) from the 4
immunized but protected animals (Fig. 6), indicative of
uninfected status.
Discussion
Our results demonstrate that a multi-protein HIV-1 DNA/
MVA vaccine is capable of protecting animals from infection
by repeated intrarectal challenges with a highly heterologous
SHIV. These results would clearly not have been expected
based on many previous studies where similar vaccine
regimens eliciting cellular immunity protected animals from
disease progression but not infection by homologous virus
challenge (Amara et al., 2001; Barouch and Letvin, 2000;
Barouch et al., 2001b; Rose et al., 2001; Shiver et al.,
2002). Therefore, the application of the repeated dose
exposure approach to vaccine evaluation may uncover
aspects of protection and efficacy not appreciated by single
higher dose exposure approaches. Furthermore, this method
of expanding the exposure window through multiple
challenges permitted the evaluation of vaccine efficacy
beyond simply comparing the number of animals infected
between the control and vaccinated groups. These data
provide valuable insight into how HIV-1 vaccines eliciting
cellular immunity may behave in human trials and suggest
Fig. 5. Effect of CD8+ cell depletion on plasma viral loads. Monoclonal antibody cM-T807 was administered to rhesus monkeys 99H, M562, 94J, AC82 and M509.
Monkeys 86H and 60J received a control antibody. The injection of antibody is indicated by arrows. (A and C) CD8+ T cells were enumerated by four-color flow
cytometric analyses. (A and B) Monkeys protected beyond 17 intrarectal challenges. (C and D) Systemically infected macaques that had controlled plasma viremia to
below detection. (B and D) Plasma levels of viral RNA. As marked on each graph, the sensitivity limits are 100 copies/mL for plasma.
221D. Ellenberger et al. / Virology 352 (2006) 216–225designing trials to assess efficacy within a framework of
partial protection.
The predictive value of non-human primate models for HIV-
1 vaccine efficacy hinges on how well the animal system
represents human circumstances (Haigwood, 2004; Nathanson
et al., 1999). The strategy of using an R5 HIV-1 envelope-based
virus, a more realistic physiologic inoculum dose, and repeatedFig. 6. Tissue lymphocyte co-cultures. Comparison of the number of positive co-cultu
uninfected vaccinees. Virus was propagated for 28 days in culture and analyzed on th
was done using p27 antigen capture kits according to the manufacturer's directions
testes, and light-colored gray bars represent lymph nodes.mucosal exposures to achieve infection was employed in this
study to more closely mimic human sexual HIV-1 transmission.
Other investigators are also pursuing the development of repeat
exposure models to infect non-human primates using different
routes of exposure and different viral challenge strains (Ma et
al., 2004; Otten et al., 2005; Van Rompay et al., 2005). The
challenge dose used in this study is approximately 5-fold higherres demonstrating evidence of spreading viral infection in infected monkeys and
e basis of p27 values obtained from culture supernatants. Quantification of Gag
. White bars represent gut-derived tissues, filled dark bars represent spleen and
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(Pilcher et al., 2004), a period of presumed high transmission
risk (Cohen and Pilcher, 2005). Other animal challenge models
may use in excess of 103 to 105 50% tissue culture infective
doses in single or multiple high dose challenges when
evaluating a potential vaccine regimen (Allen et al., 2002;
Nixon et al., 2000; Van Rompay et al., 2005). The combination
of a highly transmissible inoculum dose and repeated exposures
results in a rigorous challenge system in which an average of
only 4.6 exposures was necessary to achieve infection among
all our real-time and historic control animals combined (total
n = 14, data not shown). While high-dose single exposure
systems may still be advantageous for issues related to
pathogenesis, repeat exposure systems can provide distinct
advantages for the pre-clinical evaluation of interventions
designed to prevent infection as recently concluded by Regoes
et al. using virtual experimental simulations (Regoes et al.,
2005).
Understanding correlates of protection from HIV-1 infection
would dramatically advance progress towards vaccine imple-
mentation and ideally requires a system of study, such as the
repeat exposure system, that provides a clear distinction among
vaccinated individuals based on susceptibility to infection. The
model described here is among the first to provide such a
distinction. Furthermore, the repeated exposure approach
allows for more sophisticated hazard models to be applied for
direct evidence of an association between immune response
parameters and susceptibility to infection. However, no obvious
specific or non-specific correlate of protection was evident in
this study between animals based on susceptibility. In addition
to comparing pre-challenge cellular (Figs. 3 and 4) and humoral
immune responses, we also measured cellular and humoral
anamnestic responses and found no significant differences to
distinguish animals based on their susceptibility (data not
shown). We also found no significant differences in the ability
to infect PBMCs in vitro with the challenge virus regardless of
the animal's susceptibility to infection in the repeat exposure
model (data not shown). Such findings suggest that specific
mechanisms of immune protection against HIV-1 infection are
complex and may not necessarily involve only these cellular
responses previously associated with protection from disease
progression (Allen et al., 2000; Barouch et al., 2001a; Vogel et
al., 2002). A similar conclusion was reached in studies of
animal re-challenge after antiretroviral intervention during
initial acute infection (Lifson et al., 2001) and oral challenge
of vaccinated infant macaques (Van Rompay et al., 2005) where
little or no viral-specific cellular and humoral immunity was
associated with reduced pathogenesis.
Moreover, a combination of local and systemic immune
mechanisms, including nonspecific barriers, adaptive immune
responses and innate host defense mediators, may be necessary
to provide full protection against HIV-1 exposure. Character-
izing these resistance factors present at the mucosal site of
exposure will be important adjuncts to understanding vaccine-
elicited protection. Furthermore, the system we describe here
may be adapted to efforts aimed at uncovering natural resistance
or other yet undefined mechanisms as has been implicated inhighly exposed persistently seronegative individuals which
remain uninfected despite repeated exposure to virus (Kulkarni
et al., 2003). Frequent and repeated exposure to virus may be
important in maintaining a combination of specific and non-
specific mucosal resistance necessary to prevent infection (Kaul
et al., 2001).
The repeat exposure method expands the challenge window
and, in theory, may allow the vaccine-elicited immune memory
an opportunity to be recalled and recruited to the site of mucosal
exposure. Examination of the mucosal lymphocytes found in
the lamina propria of protected animals upon necropsy will also
provide meaningful insight into mechanisms of protection as the
gut CD4/CCR5-expressing effector lymphocytes are demon-
strated crucial sanctuaries for SIV and HIV-1 production
(Brenchley et al., 2004; Li et al., 2005; Mattapallil et al.,
2005; Veazey et al., 1998). However, had these animals actually
harbored subclinical infection as the basis for their apparent
protection, we would have expected some measurable viremia
following CD8 depletion as observed by others (Jin et al., 1999;
Lifson et al., 2001; Schmitz et al., 1999). The resulting burst of
viremia and subsequent control in the systemically infected
animals (Fig. 5D) does indeed support the importance of
cellular immunity in suppressing HIV and SIV infections
(Borrow et al., 1994; Cranage et al., 1997; Gallimore et al.,
1995; Greenough et al., 1997; Koup et al., 1994; Matano et al.,
1998, 2004; Schmitz et al., 1999).
Ultimately, the efficacy of HIV-1 vaccines eliciting cellular
immunity will most likely be determined in human trials.
Current presumptions that these vaccine regimens will only
impact HIV-1 disease progression are largely derived from non-
physiological high-dose and/or intravenous challenges of non-
human primates that may overwhelm moderately efficacious
vaccines and provide little or no protection from infection
(Cranage et al., 1997; Gallimore et al., 1995; Jin et al., 1999).
This report advocates that an HIV-1 DNA/MVA vaccine can
provide reasonable protection from infection against a highly
heterologous challenge virus, should help guide future vaccine
evaluation, provide insight into protection/resistance mechan-




The construction of the DNA and MVA immunogens has
been previously described (Ellenberger et al., 2005). Briefly, the
DNA vaccine prime expressed HIV-1 Gag, Pol, Tat, Rev, Vpu
and Env (GenBank accession no. AY227361 and AY227362)
and the MVA boost expressed matched Gag, Pol and Env
proteins from a circulating recombinant form CRF02_AG
(Ellenberger et al., 2002, 2004).
Immunizations
The immunization protocol has been previously described
(Ellenberger et al., 2005). All animal protocols were approved
223D. Ellenberger et al. / Virology 352 (2006) 216–225by the Institutional Animal Care and Use Committees at both
the Caribbean Primate Research Center and Centers for Disease
Control and Prevention.
Challenge virus stock and animal inoculations
SHIV SF162P3 was obtained from the NIH AIDS Research
and Reference Reagent Program (catalog no. 6526) for use in
the present study. The in vitro tissue culture infectious dose
(TCID) was verified on Con-A stimulated rhesus macaque
PBMC (CD8-depleted). Endpoint TCID was used as a guide for
the inoculum's level (Otten et al., 2005). The virus stock was
diluted with RPMI to 10 TCID/mL (3.8 × 105 viral particles) for
in vivo rectal inoculations.
All virus exposures involved atraumatic inoculation of cell-
free virus (1 mL) into the rectal cavity via a sterile gastric
feeding tube of adjusted length. Anesthetized macaques
remained recumbent for 15 min following each IR inoculation
that occurred on an approximate weekly basis.
Seven months after MVA boost; the initial SHIV challenge
of two vaccinated and two naïve control monkeys was
completed. Eleven months after the MVA boost, the remaining
14 vaccinated monkeys were challenged weekly. Using the
same SHIV162P3 challenge stock, a total of 14 naïve rhesus
monkeys (including 12 naïve control monkeys from past and
current intervention studies) have received weekly challenges.
Evidence of systemic infection
Cell-free and cell-associated virus load assays were com-
pleted as previously described in detail (Otten et al., 2005).
Briefly, the cell-free virus load (plasma viremia) was assessed
by quantifying viral RNA in blood plasma by use of a reverse
transcriptase polymerase chain reaction (PCR) assay system.
The Taqman real-time 5′ nuclease technique was used to detect,
amplify, and quantify cell-associated proviral DNA from
PBMC samples. A synthetic-peptide EIA (Genetic Systems
HIV-1/HIV-2) was used for detection of virus-specific serologic
responses. Reactive specimens were confirmed by SIV-specific
Western blot analysis (ZeptoMatrix).
Peptide pools
HIV-1 subtype CRF02_AG peptides were 15mers over-
lapping by 11 matched to the vaccine strain. HIV-1 subtype A
and CRF01_AE peptides were similarly 15mers overlapping by
11. Consensus B peptides were obtained from the NIH AIDS
Research and Reference Reagent Program (catalog #5107).
Peptides pools contained 25 sequential peptides. Peptides were
dissolved in DMSO at 50–100 mg per ml and stock solutions
maintained at −70 °C. Peptide working solutions were kept at
−20 °C for 1 week.
T-cell assays
ELISPOT assays were done as previously described
(Ellenberger et al., 2005) except that 2 μg/ml of antibody tohuman CD28 and CD49d (Becton Dickinson, San Jose, CA)
were included in incubations (Waldrop et al., 1998). Intracellular
cytokine staining (ICS) for IFN-γ and IL-2 has been described
previously (Amara et al., 2001, 2002; Ellenberger et al., 2005).
Depletion of CD8+ T cells in vivo
Five rhesus monkeys were administered the mouse–human
chimeric monoclonal antibody to CD8 (cM-T807) and 2
monkeys were administered a control antibody (IVIg) subcu-
taneously at 10 mg of antibody per kilogram of body weight.
Three and 7 days later, antibodies were given at 5 mg of
antibody per kilogram of body weight intravenously as a slow
bolus. Peripheral blood samples were drawn prior to antibody
injection.
Phenotypic analysis of cell subsets
Four-color flow cytometric analyses of whole blood samples
were performed to monitor changes in the T cell populations.
Cells were analyzed by using monoclonal antibodies with
proven cross-reactivity to rhesus macaque's cells. Phycoery-
thrin (PE) labeled anti-human CD3 and CD4 (BD Pharmingen,
San Diego, CA) and anti-human CD8, clone DK25, (DakoCy-
tomation, Carpinteria, CA), were used to stain fresh PBMC
from both treated and control animals. Natural killer cells were
measured by using PE-labeled anti-human CD56 and CD16
monoclonal antibodies. Ten μl of antibodies were mixed and
added to 100 μl of whole blood then incubated for 1 h in the
dark. Red blood cells were lysed by incubation for another
10 min at room temperature with an Immunoprep Reagent
(Beckman-Coulter). Stained PBMC were washed with 3 ml of
PBS, resuspended in 0.5 ml of PBS containing 1.5%
paraformaldehyde and analyzed by using a FACSCalibur
flow cytometer and the CELLQUEST (Becton-Dickinson)
software. Absolute values of CD4, CD8, and NK cells were
calculated from complete blood cell count results.
Tissue lymphocyte isolation and co-culture
Isolation of mononuclear cells from gut-associated tissue
necropsies (jejunum, duodenum, ileum, cecum and colon) were
done using the collagenase type II method, and lymph nodes
(peripheral, axillary and mesenteric) and spleen cells were
teased into single cell suspensions as previously described
(Shacklett et al., 2003). Co-cultures were established with Con
A-stimulated CD8 T cell depleted macaque feeder PBMC and
monitored for 28 days for the presence of Gag by using SIV
Core Antigen kit (Beckman Coulter, Fullerton, CA).
Statistical analysis and modeling of outcome data
All statistical analyses were done using SAS. Inferences
regarding vaccine efficacy were based on a discrete time
transmission probability model which allows for both “leaky”
and “all-or-none” effects of vaccination (Longini and Halloran,
1996). This model treats the number of exposures as the time
224 D. Ellenberger et al. / Virology 352 (2006) 216–225scale and assumes the probability of infection is independent
of the number of prior exposures. Maximum likelihood
estimates were obtained using standard numerical techniques.
Likelihood ratio tests were used to compare nested models and
profile likelihood was employed to obtain confidence inter-
vals. Goodness-of-fit assessment was completed using the
Kolmogorov–Smirnov test.
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